The Low DoseThe GLP-1 price desk
Briefing

PlexusDx vs Ozari Health

$189/mo against $125/mo for tirzepatide. Which is worth it, and for whom.

Updated 2026-09-18

DISCLOSURE — Coreage Rx pays this desk a commission when a reader signs up through our link. It buys no ranking, no score and no deletions. Method: how we rate. Full terms: disclosure.

Both sell tirzepatide. Ozari Health costs $125 a month and PlexusDx costs $189, a difference of $64 a month or about $768 a year. The desk reads it as follows.

PlexusDx is pharmacy transparency and genetic testing. Ozari Health is lowest advertised semaglutide price. They are not aimed at the same person, and the cheaper one is not automatically the right answer — though on this board it usually is.

Side by side

PlexusDxOzari Health
Advertised from$129$125
Membership on topNoneNone
True monthly cost$189$125
Roughly, per year$2,268$1,500
Price includes medicationYesYes
Names its pharmacyYesNot published
Our score4.4 / 54.4 / 5

Prices verified 2026-09-18. "True monthly cost" is what you are billed in month two, once any introductory rate has lapsed and any membership has renewed.

Where PlexusDx wins

  • The most detailed pharmacy disclosure in this comparison — six named 503A partners.
  • Names its prescribing physicians along with their NPI numbers.
  • No membership fee, and flat pricing across the dose range.
  • Genetic and blood testing available alongside the prescription.

The advertised "from $129" is the programme floor. Budget $189/month for the compounded injection tier.

Where Ozari Health wins

  • The lowest advertised compounded semaglutide price we have verified.
  • No membership fee and free expedited shipping included.
  • Names its physician network and medical directors.
  • Cancel-anytime with no commitment required.

Confirm whether $86 is a month-to-month rate or requires a longer commitment, and ask which pharmacy compounds it.

How they score

What we weighWeightPlexusDxOzari
True monthly cost30%4.65
Price honesty20%4.54.4
Clinical support20%3.83.9
Pharmacy sourcing15%4.93.8
Cancelling15%44.3

PlexusDx scores higher overall at 4.4 out of 5. The weights are published on how we rate, and so is the note about which of these is our paid featured partner.

Which should you pick?

  • Pick Ozari Health if cost is the binding constraint. Over a year the gap is about $768, which is real money for the same class of medication.
  • Pick PlexusDx if what it does better matters to you — the most detailed pharmacy disclosure in this comparison — six named 503a partners.
  • If sourcing matters, note that PlexusDx publishes which pharmacy compounds its medication and Ozari Health does not.

The verdict

On the board, Ozari Health at $125 a month is the more defensible choice on arithmetic alone. PlexusDx earns its premium only if you will actually use what it does differently. Read the full reviews before deciding: PlexusDx and Ozari Health.

How they sit against everyone else

ProgrammeAdvertisedBilledGapVs board floor
Coreage Rx$149$199+$50+$74/mo
Trimi$125$125none
Ozari Health$125$125none
Fifty 410$133$133none+$8/mo
PlexusDx$129$189+$60+$64/mo
Ivím Health$199$199none+$74/mo
Zealthy$216$216none+$91/mo
Hims & Hers$199$238+$39+$113/mo
Coby Health$179$239+$60+$114/mo
Mochi Health$199$278+$79+$153/mo
Eden$199$298+$99+$173/mo
Lemonaid Health$229$348+$119+$223/mo

More from the desk

  • PlexusDx tirzepatide review

    Advertised at $129, billed at $189. Position 5 of 18 on our board.

  • Ozari Health tirzepatide review

    Advertised at $125 and billed at $125 — no gap. Position 3 of 18 on our board.

  • How to spot a bad seller

    The FDA sent more than 55 warning letters to online GLP-1 sellers in one day. Here is how to tell a licensed programme from the rest.

  • The twelve-month cost

    Month one is the cheapest month you will have. Here is the full-year arithmetic, including the costs nobody puts in the advert.

  • Cheapest right now

    Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.